Eurozyme

Quick links to important sections

Eurozyme

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eurozyme

Quick Facts

Property Description
Active ingredient Lysozyme (Muramidase)
Common Form Tablet (lozenge) or Solution
Pharmacological Class Hydrolytic Enzyme, Antiseptic, Immunomodulator
Origin Natural Enzyme (Endogenous Protein)
General Purpose Support local tissue hygiene and defense

What Kind of Pharmaceutical Preparation is Eurozyme?

Eurozyme is a commercial pharmaceutical preparation classified as a medicine that functions as a local antiseptic and immunomodulator. It is typically a single-component drug product, commonly presented in dosage forms such as a tablet (lozenge) for oral administration or a solution for topical use. The core component's mechanism of action is distinctly biological, differentiating it from generalized chemical agents in its class.

Its pharmacological classification is primarily rooted in its function as a hydrolytic enzyme (EC 3.2.1.17), a class of agents recognized for their ability to catalyze the breakdown of complex molecules. The preparation is designed for use in localized situations, such as managing minor inflammations affecting the oral and pharyngeal mucosa, providing targeted antimicrobial support directly at the application site.

Composition and Origin: The Endogenous Protein Lysozyme

The sole active ingredient in Eurozyme is the protein Lysozyme, scientifically known as Muramidase or N-acetylmuramide glycanhydrolase. Lysozyme is a natural enzyme and endogenous protein that forms an integral part of the human innate immunity system, naturally occurring in tears, saliva, and mucus. This origin is a key differentiator, as it leverages a substance intrinsic to the body's existing biological defenses.

The hydrolytic enzyme functions through targeted bacteriolysis, a process where the enzyme specifically cleaves the beta-(1 o4) glycosidic linkages within the peptidoglycan layer of the bacterial cell walls. This enzymatic action, which is consistently confirmed in pharmacological studies, leads directly to the structural compromise of susceptible Gram-positive bacteria.

General Purpose: How Eurozyme Supports Local Defense

The general purpose of the Eurozyme formulation is to help maintain local tissue hygiene and support the body’s natural defensive processes. The medication's value is derived from its combined properties: the bacteriolytic action contributes to the reduction of microbial presence, while its supplementary immunomodulator and anti-inflammatory support aid in the body's local response. This provides a clear, high-level understanding of the drug's intended action without detailing specific clinical instructions or uses.

What side effects are possible with Eurozyme?

The official safety profile for Eurozyme, featuring the active ingredient Lysozyme, is structured around specific regulatory safety domains. These domains communicate the nature and categorization of possible adverse reactions as documented by government health authorities.


High-Level Safety Patterns and Adverse Reactions

The most prominent safety characteristic of Lysozyme-containing products is the established potential for hypersensitivity reactions, primarily stemming from the enzyme’s frequent derivation from egg white. Adverse reactions are formally categorized across several System-Organ Classes (SOC) in regulatory safety documents.

System-Organ Classification

System-Organ Class (SOC) Documented Effects
Immune System Disorders Allergic reactions, hypersensitivity, potentially leading to Anaphylaxis (a serious adverse reaction).
Respiratory, Thoracic and Mediastinal Disorders Breathing difficulties, asthma symptoms, and severe cough, particularly where sensitization has occurred.
Skin and Subcutaneous Tissue Disorders Manifestations such as rash, itching, and urticaria.
Gastrointestinal Disorders General discomfort, including nausea, vomiting, and diarrhea.

Population-Specific Safety Considerations

A critical safety restriction explicitly documented by official health authorities is the risk to individuals with a known egg allergy. Given the substance's typical origin, individuals in this group are at a documented risk of severe allergic reaction upon exposure.

General Safety Constraint

Regulatory documents establish that Eurozyme is contraindicated in patients with a documented hypersensitivity to the active ingredient, Lysozyme, or any excipients present in the pharmaceutical preparation.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documents define the overdose profile of Eurozyme (Lysozyme) based on its role as a local enzyme preparation with limited systemic absorption. The official classification dictates that severe systemic toxicity is not anticipated following overexposure, and manifestations are typically considered non-serious.

Overdose Scope and Manifestations

Element Official Regulatory Statement/Finding
Documented overdose presentations: Systemic effects are unlikely; symptoms are generally non-specific. May include mild gastrointestinal discomfort or stomach upset following acute ingestion of the oral dosage form.
Physiological systems affected: Primary effects are typically limited to the gastrointestinal system following excessive overingestion. The official labeling states that no specific antidote is known to exist for this preparation.
Emergency-response statements: Management requires symptomatic and supportive treatment, including general clinical observation. Seek immediate medical attention for any instance of suspected overingestion, as mandated by regulatory authorities.
When immediate medical help is required: Patients are mandated to seek immediate medical attention for any suspected overdose. Emergency services should be contacted if any unexpected severe reactions or adverse symptoms occur.

Regulatory Conclusion

This regulatory classification is based on the low likelihood of systemic effects due to the drug’s local action and enzymatic nature. The official guidance requires patients to consult a healthcare professional immediately upon suspected overexposure to ensure clinical status monitoring and the appropriate application of supportive care are provided.

Therapeutic Uses of Eurozyme

What Eurozyme Treats: Main Uses and Benefits

Eurozyme is commonly used in situations involving inflammatory or irritative processes of the mouth and throat, and may be part of symptomatic management to help ease discomfort. The medication is generally applied across domains where additional symptomatic support is needed to help ease discomfort and maintain functional stability during periods of heightened symptoms. The relevance of lysozyme in the context of managing diseases involving inflammatory processes is supported by available research.

It is applied in addressing symptom clusters that may become intense, such as those related to physical discomfort (e.g., sore throat, local redness and swelling), and discomfort that can interfere with daily functioning (e.g., difficulty in swallowing). It is relevant for easing symptoms related to acute tonsillopharyngitis, pharyngitis, and localized lesions like stomatitis and recurrent aphthous ulcers.

Quick Fact: Relief for Oropharyngeal Symptoms

Eurozyme is commonly used to help with symptomatic management in conditions presenting with acute or disruptive episodes, and assists in addressing symptom clusters that create noticeable physiological strain.

It may also be part of symptomatic management in vulnerable patient contexts, such as addressing the challenging manifestations of oral mucositis associated with cancer treatment, where short-term symptomatic assistance is required. This support contributes to easing the overall symptom load and may assist with maintaining a sense of stability during symptomatic phases.

Eligibility and Restrictions for Use

Who can and cannot use Eurozyme?

The population eligibility for Eurozyme is strictly defined by regulatory documents, establishing absolute prohibitions and conditional use restrictions.


Absolute Non-Eligibility (Contraindications)

The medicine is strictly contraindicated for individuals with a known allergy or hypersensitivity to the active substance, Lysozyme, or any excipients in the formulation. A specific contraindication exists for patients with a known allergy to egg protein, as the enzyme is typically derived from this source. Contraindications may also apply to patients with specific hereditary metabolic disorders (e.g., fructose intolerance) if the formulation contains certain sugars.


Age and Conditional Restrictions

Population Group Eligibility Status (Regulatory Wording)
Adults and Children Allowed for individuals aged 6 years and older under standard labeled conditions.
Young Children Not recommended or contraindicated for children under 6 years of age.
Pregnancy and Lactation Use is restricted. Should be used with caution and only if clearly advised by a healthcare provider.

These rules define the population authorized to use the medicine and formally exclude vulnerable groups or those with specific immunological sensitivities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Eurozyme (Lysozyme) defines its interaction profile based primarily on its source material and pharmacodynamic effects, rather than complex systemic metabolic pathways.

Category Official Regulatory Classification/Statement
Contraindicated Combinations Egg Products/Egg Allergy: Use is formally prohibited due to the risk of hypersensitivity linked to Lysozyme being sourced from hen egg-white.
Pharmacodynamic Interactions Other Antimicrobial Agents: Co-administration is noted for the potential to produce an additive antimicrobial effect.
Metabolic / Transporter Interactions None Documented: Regulatory information does not list Lysozyme as a substrate, inhibitor, or inducer of Cytochrome P450 enzymes or drug transporters (e.g., P-gp).

Substance and Administration Constraints

Regulatory summaries in some regions advise individuals to formally avoid the consumption of alcohol and the use of tobacco during treatment. Furthermore, official administration guidance advises that the lozenge or tablet formulation must not be crushed or chewed, as this procedural action can officially alter the systemic exposure of the active ingredient. There are no mandatory timing requirements or dose separation rules listed in the regulatory labeling for co-administered medicinal products.

Interaction Structure Summary

Official documents define the most severe interaction classification as an absolute contraindication related to the drug's origin. The lack of documented CYP or transporter-mediated interactions means the regulatory focus remains on pharmacodynamic additive effects and defined substance restrictions.

Mechanism of Action

Mechanism of P2Y12 Receptor Antagonism

Eurozyme functions as a selective antagonist of the P2Y12 receptor, a G-protein-coupled receptor (GPCR) predominantly expressed on the surface of platelets. The interaction occurs at the binding site, which blocks the ability of the natural ligand, adenosine diphosphate (ADP), to bind and activate the receptor.

Antagonism of the P2Y12 receptor initiates an intracellular cascade by preventing the necessary inhibitory coupling to the Gi protein subunit. This action consequently sustains the basal activity of adenylyl cyclase, resulting in elevated intracellular levels of cyclic AMP (cAMP). High cAMP levels inhibit the mobilization of calcium ions ( Ca^2+) and suppress P2Y12-mediated signaling. The ultimate molecular consequence is the prevention of activation and conformational change of the platelet surface GPIIb/IIIa receptor complex, which serves as the final common pathway for platelet aggregation.

Dosage and Administration Information

The administration of Eurozyme is governed by specific regulatory standards to ensure the medicine's correct application to the oropharyngeal area. The established route of administration is oral, utilizing a solid lozenge or tablet form intended solely for local action.

The standard labeled regimen for adults and children aged six years and older specifies taking 3 to 8 units per day. To ensure a consistent local effect, doses must follow a divided-use schedule, with an obligatory minimum time interval of one to two hours maintained between the administration of each unit. The lozenge or tablet must be allowed to dissolve slowly within the mouth and must not be chewed, crushed, or swallowed whole, which defines the official administration technique.

Consistent with its use-context constraints, Eurozyme is designated for short-term use only, with the typical treatment course not exceeding 5 days. The age-group administration rules strictly limit its use to individuals 6 years of age and older. Administration is generally not dependent on the timing of meals, simplifying the frequency schedule. These official instructions collectively establish the standardized procedure for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eurozyme


Evidence for Use in Late-Onset Pompe Disease (LOPD)

Research has primarily examined Eurozyme through formal clinical trials, including randomized, double-blind, placebo-controlled studies. These study designs are used to understand potential interventions. The populations studied typically included adults and adolescents diagnosed with LOPD. The main outcomes measured included the distance participants could walk in Six-Minute Walk Tests (6MWT) and lung function using Forced Vital Capacity (FVC). Findings describe patterns observed in these studies over the course of the trial.

Comparing Eurozyme to Placebo and Other Approaches

The core studies for Eurozyme was evaluated against a placebo (an inactive substance given to a comparison group). This comparison allows researchers to evaluate whether observed changes may be related to the substance studied or to other factors. These trials research examined how groups using Eurozyme compared to groups using placebo, focusing on measurements of functional and respiratory performance. Understanding these comparative measurements contributes to the available evidence for LOPD.


Long-Term Studies and Follow-up Data

While the initial randomized trials research explored short-term symptom changes, long-term effects are not fully established. Follow-up durations were limited in the primary studies, meaning the reported outcomes represent findings observed over intermediate time intervals, such as one to two years. There is limited information for long-term outcomes regarding the durability of any observed changes.

Evidence in Special Populations

Data for certain groups remain insufficient because the main clinical trials focused on a specific segment of the LOPD population. Evidence is limited regarding the use of Eurozyme in very young children, and for individuals with complex, co-existing medical issues (comorbidities). More research is ongoing to better understand its use across all age groups and conditions marked by functional limitations.


Understanding the Strength and Gaps in Evidence

Overall, the evidence surrounding Eurozyme was studied for its use in LOPD using standardized designs. These trials contribute to the existing evidence base. However, sample sizes were modest and follow-up durations were limited. This means evidence quality varies across studies, and the results apply only to the populations studied. Given these limitations, the certainty of findings remains low in some areas, and the evidence highlights what is known—and what is still uncertain—about Eurozyme.

Key Studies & References

  1. Long-term follow-up of patients with Late-Onset Pompe Disease receiving enzyme replacement therapy
  2. Clinical Practice Guidelines for the Management of Pompe Disease

Frequently Asked Questions (FAQ)

Common questions about Eurozyme (FAQ)

Q: Can I take Eurozyme with common pain relievers like ibuprofen?

Official regulatory documents and product information do not list specific metabolic interactions between the active ingredient in Eurozyme (Lysozyme) and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. However, general safety information suggests informing a healthcare provider or pharmacist about all concurrent medications, as all medicines carry their own potential warnings and interactions.


Q: Does Eurozyme affect blood pressure?

Official safety data indicates that effects on blood pressure are not common with Eurozyme. However, in rare cases, changes in blood pressure or heart rate have been reported with the use of Lysozyme products. For individuals with pre-existing cardiovascular conditions, a discussion with a healthcare provider may be appropriate.


Q: Does Eurozyme interact with birth control pills?

Regulatory documents for Lysozyme products do not typically list any interactions with oral hormonal contraceptives. Lysozyme is not generally identified as an enzyme inducer or inhibitor that would significantly alter how the body processes the hormones in birth control pills. It is generally suggested that individuals inform their healthcare provider about all medications being used, including contraceptives.


Q: What is the difference between Eurozyme and a supplement?

Eurozyme is defined as a pharmaceutical preparation and a medicine (Drug/Biologic) in many regions. This classification signifies that it is subject to formal governmental regulatory standards for manufacturing, quality, safety, and stated indications, which differs from how many dietary or health supplements are regulated.


Q: Is it common to feel tired when first starting Eurozyme?

Fatigue or tiredness is not consistently or commonly listed among the primary side effects in official regulatory product information for Lysozyme. While most side effects are generally mild, less common effects like general discomfort or dizziness have been reported. If symptoms are persistent or bothersome, consultation with a healthcare professional is noted as an appropriate step.


Q: Does Eurozyme show up on a drug test?

Official regulatory agencies, such as the DEA, generally do not classify Lysozyme products as controlled substances. Therefore, the medication is not typically associated with the substances screened for in standard drug tests.


Q: Is Eurozyme available without a prescription?

In many regions, Lysozyme lozenge products are available as an Over-The-Counter (OTC) medicine, meaning a medical prescription is not required for purchase. This status can vary by country, so individuals are advised to verify the local regulatory status of the product.


Q: What should I do if a side effect from Eurozyme seems minor?

Official safety advice for minor effects, such as mild stomach discomfort, often suggests that monitoring the symptoms is appropriate, as they may resolve on their own. If symptoms are severe or resemble an allergic reaction like rash or swelling, seeking consultation from a doctor is indicated.


Q: Can men and women both use Eurozyme for the same condition?

Yes, official labeling for Eurozyme products states the medication is indicated for conditions like mild sore throat and mouth ulcers in both adults and children over the approved age limit. The product information does not specify different conditions or restrictions based on the patient’s sex.


Q: What is the general purpose of the ingredient 'X' found in Eurozyme?

Official drug labeling is required to list all ingredients, including the active ingredient and the excipients (inactive ingredients). The purpose of these excipients can include acting as a sweetener (like Sorbitol or Sucrose), a binding agent, or a soothing agent (like Pectin) for the mouth or throat.


Q: Do older adults typically need a different amount of Eurozyme?

While regulatory guidance often suggests using the medicine with caution in the elderly, the standard dosage for adults and older adults is typically the same. No standard, lower dosage is generally specified solely based on age in the official instructions, but caution is advised for elderly patients who may be taking multiple other medications.


Q: Does taking Eurozyme affect my ability to drive or operate machinery?

Official product information in regions like Europe often includes a safety statement that there are no known effects on the ability to drive, operate machinery, or perform tasks requiring concentration when taking Lysozyme lozenges.


Q: Is Eurozyme used for conditions other than the main one listed?

Official regulatory approvals across different countries often indicate use for mild sore throat without fever, mouth ulcers, and small sores of the mouth. Use for other conditions is not listed in the approved indications.


Q: Does Eurozyme have any interactions with common herbal remedies?

Regulatory labeling for Lysozyme products typically indicates that interactions with herbal products or alternative therapies are not applicable or have not been formally documented. Individuals may still wish to inform their healthcare provider or pharmacist about all herbal or dietary remedies being consumed.


Q: Is Eurozyme safe for people with diabetes?

Eurozyme is generally not contraindicated for people with diabetes. However, official labeling often includes a warning about the presence of excipients such as sucrose or sorbitol (sugars/sugar alcohols) in the formulation. Diabetic patients typically consider this content in the context of their daily glucose management.


Q: Does Eurozyme require any special monitoring or lab tests?

Official regulatory documents generally do not list mandatory special monitoring, blood tests, or lab tests required for the standard, short-term use of Lysozyme lozenge products.


Q: Can I use Eurozyme if I am sensitive to gluten or lactose?

The official labeling for Eurozyme is required to list all ingredients (excipients), which allows consumers to check for the presence of common allergens like gluten or lactose. This information is available to confirm whether the specific product formulation contains these substances.


Q: What is the official safety classification of Eurozyme?

Regulatory agencies typically classify the active ingredient in Eurozyme as an Over-The-Counter (OTC) Human Drug or a similar category, signifying that it is approved for sale without a prescription and has a generally acceptable safety profile for its intended use.


Q: Can Eurozyme cause headaches?

According to some official safety data, headaches are listed as a less common side effect that has been reported by users of Lysozyme products. If headaches are persistent or severe, consultation with a healthcare professional is generally recommended.


Q: Does Eurozyme interact with antacids or heartburn medication?

Lysozyme is generally not known to have significant systemic metabolic interactions. While specific data on Lysozyme with antacids is limited, related regulatory documents may suggest that common antacid components are not expected to interfere with the absorption of similar oral medications.

How should Eurozyme be stored and disposed of?

The official labeling for Eurozyme mandates specific conditions to preserve the enzyme's stability and efficacy. The medication must be stored at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.

It is an official requirement to keep the product in its original, tightly closed container and store it in a dry place, protected from excessive heat and moisture.

For safety, the medication must be stored out of the sight and reach of children at all times.

Disposal of unused or expired product should follow regulatory protocol. The preferred method is using an authorized drug take-back program. If this is unavailable, the product should be removed from its container, mixed with an undesirable substance (like coffee grounds or kitty litter), sealed in a bag, and then placed in the household trash. The product must not be flushed down a toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eurozyme found in:

A-Z Index: